2018E looks set to be a significant year for Collagen Solutions’ lead ‘finished product’ ChondroMimetic. The company expects to report key clinical data during Q1/18E and assuming a positive outcome, submit for the CE mark and secure further partners for the product during the year. We believe the company is also strengthening its existing business stating its sales pipeline is ‘the strongest it has been’. We maintain our Buy recommendation.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ChondroMimetic’s 2018
- Published:
02 Feb 2018 -
Author:
Chris Donnellan -
Pages:
21
2018E looks set to be a significant year for Collagen Solutions’ lead ‘finished product’ ChondroMimetic. The company expects to report key clinical data during Q1/18E and assuming a positive outcome, submit for the CE mark and secure further partners for the product during the year. We believe the company is also strengthening its existing business stating its sales pipeline is ‘the strongest it has been’. We maintain our Buy recommendation.